Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?
Yıl: 2016 Cilt: 13 Sayı: 2 Sayfa Aralığı: 88 - 94 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?
Öz: Profilaktik bilateral salpingo-ooferektomi BRCA 1/2 mutasyonlu ka-dınlarda kanser riskinin azaltılması için birçok ülkede yaygın olarak uygulanmaktadır. Tümör supresör genler olan BRCA 1/2 gen mutas-yon taşıyıcılarında, yaşam boyu, meme ve over kanseri yakalanma riski daha yüksektir. BRCA 1/2 gen mutasyonları ile meme ve over kanser-leri arasındaki ilişkinin ortaya konması ile pro laktik bilateral sal ngo-ooferektominin over kanserine olduğu kadar meme kanseri için de ko-ruyucu etkisinin mevcut olduğu düşünülmektedir. Genetik mutasyon analiz testlerinin yapılabilirliğinin artması ile risk azaltıcı cerrahinin yararları ve etkileri konusunda birçok tartışma ortaya atılmıştır. Risk azaltıcı stratejinin seçiminde, en uygun yöntemin hangisi olduğuna dair net sınırlar olmadığı için, hasta ve sağlık personeli açısından tar-tışmalı bir konu olmaya devam etmektedir. Seçilecek risk azaltıcı cer-rahinin kanser riskine, sürveyansına ve yaşam kalitesine olan etkileri anahtar kriterlerdir. Pro laktik bilateral salpingo-ooferektomi anlamlı olarak meme kanseri riskini yaklaşık %50 ve over kanseri riskini %80-95 azaltmakta olmasına karşın buna menopoz semptomları, yaşam ka-litesinde bozulma ve hızlanmış kemik kaybı eşlik edebilmektedir. Bu derlemede, düşük ve yüksek riskli over ve meme kanserli olgularda son zamanlarda sık başvurulan bir yöntem olan pro laktik bilateral salpin-go-ooferektomi yapılmasının yarar ve zararlarının tartışılması, hemşire-lerin bu cerrahiye yönelik farkındalıklarının ve bilgi gereksinimlerinin karşılanması amaçlanmıştır.
Anahtar Kelime: Konular:
Is Prophylactic Oophorectomy Necessary to Reduce the Risk of Breast and Ovarian Cancer?
Öz: Prophylactic bilateral salpingo-oophorectomy has been widely practiced in many countries to reduce the risk of cancers in women with BRCA 1/2 mutations. BRCA1/2 gene mutation carriers with tumor suppressor genes confer a high lifelong risk of breast and ovarian cancers. Prophylactic bilateral salpingo-oophorectomy (PBSO) is considered to have a preventative effect on ovarian cancer as well as breast cancer due to the relationship between BRCA1/2 gene mutations and breast and ovarian cancers. Parallel to deŞ ning a strong relationship between BRCA-1/2 mutations and the development of breast/ovarian cancers and increasing the feasibility of genetic mutation analysis test, many controversies about the beneŞ ts and effects of risk-reducing surgeries have been raised. The impact of the preferred risk-mitigation strategies on cancer risk, survival, and quality of life are key criteria in this regard. Bilateral prophylactic salpingo-oophorectomy signiŞ cantly reduces breast cancer risk by approximately 50% and ovarian cancer risk by 80-95% but may be accompanied by menopausal symptoms, impaired quality of life, and accelerated bone loss. Therefore, decisions regarding the timing of bilateral prophylactic salpingo-oophorectomy and the use of post-bilateral prophylactic salpingo-oophorectomy hormone replacement therapy must be carefully considered. This review was conducted to discuss the beneŞ ts and disadvantages of PBSO use on low- and high-risk ovarian and breast cancer patients in addition to meeting the information requirements and awareness of nurses for this type of surgery.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
- Jemal A, Siegel R, Ward E. Cancer statistics. Cancer J. Clin 2008; 58(2):71-96. http://dx.doi.org/10.3322/CA.2007.0010
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Erişim Adresi: http://globocan.iarc.fr Erişim tarihi:15.04.2016.
- T.C. Sağlık Bakanlığı sağlık istatistiği yıllığı. 2013. http://www.saglik. gov.tr/TR/dosya/1-97020/h/saglik-istatistik-yilligi-2013.pdf. (Erişim Tarihi: 20 Şubat 2016).
- Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999; 91:1541-8. http:// dx.doi.org/1093/jnci/91.18.1541
- Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 2003; 21:593-601. http://dx.doi.org/10.1200/ JCO.2003.07.007
- Güllüoğlu B.M. Meme hastalıklarına yaklaşım: Meme kanseri için risk değerlendirmesi ve tarama stratejileri. Türk Aile Hek Derg 2008; 12(1): 9-17.
- Salhab M, Bismohun S, Mokbel K. Risk-reducing strategies for women carrying brca1/2 mutations with a focus on prophylactic surgery. BMC W o m e n ' s H e a l t h 2 0 1 0 ; 1 0 : 2 8 . h t t p : / / d x . d o i . org/10.1186/1472-6874-10-28.
- Lowery AJ, ve Sweeney KJ. The Role of prophylactic oophorectomy in the management of hereditary breast & ovarian cancer syndrome, Hysterectomy, Dr. Ayman Al-Hendy (Ed.), ISBN: 978-953-51- 0434-6, InTech, Available from: http://www.intechopen.com/books/ hysterectomy/the-role-of-prophylacticoophorectomy- in-the- management-of-hereditary-breast-ovarian-cancer-syndrome.2012 (Erişim Tarihi: 15 Aralık 2014).
- Rocca WA, Grossardt BR, Andrade M, Malkasian GD, Melton L. Survival patterns after oophorectomy in premenopausal women: a population- based cohort study. Lancet Oncol 2006; 7:821-28. http://dx.doi. org/10.1016/S1470-2045(06)70869-5
- Domchek MS, Rebbeck TR. Kanser riski yüksek kadınlarda proŞ laktik ooferektomi. Türkiye Klinikleri 2008; 2(1):8-11.
- Moscucci O, Clarke A. Prophylactic oophorectomy: a historical perspective. J Epidemiol Community Health 2007; 61:182-4. http:// dx.doi.org/10.1136/jech.2006.046474
- Parker WH, Broder MS, Liu Z, Shoupe D. Ovarian Conservation at the time of hysterectomy for benign disease. Obstetrics & Gynecology 2005; 1 0 6 ( 2 ) : 2 1 9 - 2 9 . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 9 7 / 0 1 . AOG.0000167394.38215.56.
- Lowder JL, Oliphant SS, Ghetti C, Burrows LJ, Meyn LA, Balk J. Prophylactic bilateral oophorectomy or removal of remaining ovary at the time of hysterectomy in the United States, 1979-2004. Am J Obstet Gynecol 2010; 202:538.e1-9. http://dx.doi.org/10.1016/j. ajog.2009.11.030
- Parker WH, Broder MS, Berek JS. Grand Rounds: Hysterectomy sans oophorectomy: The case for leaving a woman's ovaries alone. Contemporary Obstetrics & Gynecology 2006; 1-5. http://www.pharllc. com/wp-content/uploads/2013/03/Parker-Contemp-Obstet- Gynecol-2006.pdf. (Erişim Tarihi: 5 Nisan 2016).
- Finch A. The impact of prophylactic salpingo-oophorectomy on health in women who carry a brca1 or brca2 mutation. Thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Institute of Medical Science University of Toronto 2011.
- Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346(21 ): 609 - 15 . http://dx.doi. org/10.1056/NEJMoa020119.
- Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. JNCI 2009; 101 (2):21. http:// dx.doi.org/10.1093/jnci/djn442.
- Kauff N, Domchek S, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 and BRCA2 associated breast and gynecologic cancer: a multi-center, prospective study. J Clin Oncol. 2008; 26(8):1331-37. http://dx.doi. org/10.1200/JCO.2007.13.9626.
- Prophylactic mastectomy and prophylactic bilateral oophorectomy https://www.capbluecross.com/wps/wcm/connect/57bdf9ea-7dc4- 4e8b-a946-6b8f97166991/Prophylactic_Mastectomy_and_Bilateral_ Oopherectomy_12-1-14.pdf?MOD=AJPERES (Erişim Tarihi: 5 Kasım 2014).
- Schwartz PE. The role of prophylactic oophorectomy inthe avoidance of ovarian cancer. Int J Gynaecol Obstet 1992; 39(3):175-84. http:// dx.doi.org/10.1016/0020-7292(92)90655-3.
- Finch A, Beiner M, Lubinski J, et al. Hereditary ovarian cancer clinical study group. Salpingooophorectomy and the risk of ovarian, fallopiantube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296:185-92. http://dx.doi.org/10.1001/ jama.296.2.185.
- Finch A, Lubinski J, Moller P, Singer Christian F, Karlan B, Senter L, et. al. The impact of oophorectomy on cancer incidence and mortality in women 161 with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014; 32(15):1547-53. http://dx.doi.org/10.1200/JCO.2013.53.2820.
- Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study . Lancet Oncol 2006; 7(3):223-9. http://dx.doi.org/10.1016/S1470-2045(06)70585-X
- Larson CA. Evidence-based medicine: an analysis of prophylactic bilateral oophorectomy at time of hysterectomy for benign Conditions. Current Onco logy 2011; 18(1):13-5. PMCID: PMC3031351.
- Özcan U, Akyol D, Oransay S, Ekin M, Güngör T, Gökmen O. Controversy on prophylactic oophorectomy. Tr. J. of Medical Sciences 1998; 28:461-7.
- Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346(21):1616-22. http://dx.doi. org/10.1056/NEJMoa012158
- Piver S. Prophylactic oophorectomy: reducing the u.s. death rate from epithelial ovarian cancer. A Continuing Debate The Oncologist 1996; 1:326-30. http://dx.doi.org/10.1093/humupd/dmp037
- Sharma S. Prophylactic bilateral oophorectomy: does beneŞ ts outweigh risks. JK Science 2011;1 3(1):1-2. http://imsear.li.mahidol.ac.th/ bitstream/123456789/171969/1/jksjmer2011v13n1p1.pdf, (Erişim Tarihi17 Şubat 2016).
- Parker WH, Broder MS, Chang E, Feskanich D, Farguhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health study. Obstet Gynecol 2009; 113:1027-37. http://dx.doi.org/10.1097/AOG.0b013e3181a11c64.
- Shoupe D. Rationale for ovarian conservation in women. Menopausal Med 1999;7(3):1-4. www.asrm.org/uploadedFiles/ASRM_Content/ News_and_Publications/Journals_and_News_Letters/Menopausal_ Medicine/1999/ Menomedfall99.pdf (Erişim Tarihi: 10 Eylül 2014).
- Goldberg JI, Borgen PI: Breast cancer susceptibility testing: past, present and future. Expert Rev Anticancer Ther 2006;6:1205-1214. http://dx. doi.org/10.1586/14737140.6.8.120.
- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117-30. http://dx.doi.org/10.1086/375033.
- Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62:676-689. http://dx.doi.org/10.1086/301749.
- Gaffney DK, Brohet RM, Lewis CM, Holden JA, Buys SS, euhausen SL, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998; 47:129-136. http://dx.doi.org/10.1016/S0167-8140(98)00023-1.
- Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, et al. Survival and tumour characteristics of breast- cancer patients with germline mutations of BRCA1. Lancet 1998; 351:316-21. http://dx.doi.org/10.1016/S0140-6736(97)07065-7.
- Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997; 33:362-71. http://dx.doi. org/10.1016/S0959-8049(97)89007-7,
- Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet 1998; 352:541. PMID:9716060.
- Tranchemontagne J, Boothroyd L, Blancquaert I. Contribution of BRCA1/2 mutation testing to risk assessment for susceptibility to breast and ovarian cancer. Summary report Montreal: Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante (AETMIS) 2006; 259. d http://dx.doi.org/10.1007/s10689-005-2571-7
- Veronesi A, de Giacomi C, Magri MD, Lombardi D, Zanetti M, Scuderi C, et al: Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer 2005; 5:70. http://dx.doi. org/10.1186/1471-2407-5-70.
- Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 1998; 58:1588-92. PMID:9563465.
- Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90:1138-45. http://dx.doi. org/10.1093/jnci/90.15.1138.
- Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, et al. BRCA associated breast cancer in young women. J Clin Oncol 1998; 16:1642- 9. PMID:9586873.
- Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd OA, Menke- Pluymers MB, Bartels CC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, B. Eur J Cancer 2007; 43:867-76. http://dx.doi.org/10.1016/j.ejca.2006.12.009.
- Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652-62. http://dx.doi.org/10.1093/ jnci/dji372.
- King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286:2251-6. PMID: 11710890.
- Bramley M, Clarke RB, Howell A, Evans DG, Armer T, Baildam AD, et al: Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. Br J Cancer 2006; 94:1021-8. http://dx.doi.org/10.1038/sj.bjc.6603042
- Kote-Jarai Z, Powles TJ, Mitchell G, Tidy A, Ashley S, Easton D, et al. BRCA1/ BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Lett 2007; 247:259-65. http://dx.doi.org/10.1016/j. canlet.2006.05.003.
- Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 2003; 544:9-41. http://dx.doi. org/10.1016/S1383-5742(03)00016-4
- Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, OfŞ t K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005; 23(30):7491-6. http://dx.doi.org/10.1200/JCO.2004.00.7138.
- Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Grene MH. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers . J Clin Oncol 2005; 23(34):8629-35. http://dx.doi.org/10.1200/ JCO.2005.02.9199.
- Obermair A, Youlden DR, Bade PD, Janda M. The impact of risk- reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer--A population-based data linkage study. Int. J. Cancer 2014; 134(9):2211-22. http://dx.doi. org/10.1002/ijc.28537.
- Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996; 275:1885-1892. PMID:8648868
- Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Veer L, Garber JE, et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22:1055-62. http://dx.doi.org/10.1200/JCO.2004.04.188.
- Gençtürk N. Meme kanserinde korunma. Atatürk Üniversitesi Hemşirelik Yüksekokulu Dergisi 2007; 10(4):72-82.
- Eroğlu K, Koç G. Jinekolojik kanser kontrolü ve hemşirelik. Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi 2014; 77-90.
| APA | ÖZTÜRK R, GÜNER Ö, SEVİL Ü (2016). Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?. , 88 - 94. |
| Chicago | ÖZTÜRK RUŞEN,GÜNER ÖZLEM,SEVİL Ümran Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?. (2016): 88 - 94. |
| MLA | ÖZTÜRK RUŞEN,GÜNER ÖZLEM,SEVİL Ümran Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?. , 2016, ss.88 - 94. |
| AMA | ÖZTÜRK R,GÜNER Ö,SEVİL Ü Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?. . 2016; 88 - 94. |
| Vancouver | ÖZTÜRK R,GÜNER Ö,SEVİL Ü Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?. . 2016; 88 - 94. |
| IEEE | ÖZTÜRK R,GÜNER Ö,SEVİL Ü "Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?." , ss.88 - 94, 2016. |
| ISNAD | ÖZTÜRK, RUŞEN vd. "Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?". (2016), 88-94. |
| APA | ÖZTÜRK R, GÜNER Ö, SEVİL Ü (2016). Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?. Hemşirelikte Eğitim ve Araştırma, 13(2), 88 - 94. |
| Chicago | ÖZTÜRK RUŞEN,GÜNER ÖZLEM,SEVİL Ümran Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?. Hemşirelikte Eğitim ve Araştırma 13, no.2 (2016): 88 - 94. |
| MLA | ÖZTÜRK RUŞEN,GÜNER ÖZLEM,SEVİL Ümran Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?. Hemşirelikte Eğitim ve Araştırma, vol.13, no.2, 2016, ss.88 - 94. |
| AMA | ÖZTÜRK R,GÜNER Ö,SEVİL Ü Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?. Hemşirelikte Eğitim ve Araştırma. 2016; 13(2): 88 - 94. |
| Vancouver | ÖZTÜRK R,GÜNER Ö,SEVİL Ü Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?. Hemşirelikte Eğitim ve Araştırma. 2016; 13(2): 88 - 94. |
| IEEE | ÖZTÜRK R,GÜNER Ö,SEVİL Ü "Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?." Hemşirelikte Eğitim ve Araştırma, 13, ss.88 - 94, 2016. |
| ISNAD | ÖZTÜRK, RUŞEN vd. "Meme ve Over Kanseri Riskinin Azaltılmasında Profl aktik Ooferektomi Gerekli mi?". Hemşirelikte Eğitim ve Araştırma 13/2 (2016), 88-94. |
